Physician profile
Devanshi Gupta
NPI 1558308551
$3,968.80
in general payments reported to CMS, 2019-2025
47 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $315 · 2020: $467 · 2021: $660 · 2022: $506 · 2023: $463 · 2024: $627 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.93 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $264.96 | 2020-2022 | |
| Eisai INC. | $253.38 | 2023-2025 | |
| Biogen, INC. | $245.78 | 2019-2025 | Skyclarys, Vumerity |
| Lilly USA, LLC | $181.63 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Genentech USA, INC. | $181.02 | 2019-2025 | Ocrevus Zunovo, Enspryng, Ocrevus |
| Lundbeck LLC | $155.26 | 2022-2025 | Vyepti |
| Pfizer INC. | $144.27 | 2023-2025 | |
| Grifols USA, LLC | $139.48 | 2019-2025 | Gamunex-C |
| Novartis Pharmaceuticals Corporation | $135.84 | 2019-2025 | |
| Ucb, INC. | $122.23 | 2019-2025 | Rystiggo |
| Emd Serono, INC. | $116.23 | 2019-2022 | |
| Genzyme Corporation | $109.86 | 2019-2022 | |
| Sk Life Science, INC. | $104.65 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $96.00 | 2021-2023 | Gammagard |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devanshi Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.